-
Sawe sub-2hr marathon captured 'global imagination' says Coe
-
King Charles gets warm welcome in Bermuda after whirlwind US visit
-
Sinner shines to beat Fils, reach Madrid Open final
-
UK court clears comedy writer of damaging transgender activist's phone
-
Was LIV Golf an expensive failure for Saudis? Not everyone thinks so
-
Coe hails IOC gender testing decision
-
McInnes wants Tynecastle in 'full glory' for Hearts title charge
-
McFarlane says troubled Chelsea still attractive to potential managers
-
Man Utd boss Carrick relishes 'special' Liverpool rivalry
-
Baguettes take centre stage on France's Labour Day
-
Spurs must banish 'loser' mentality despite injury woes, says De Zerbi
-
Arsenal must manage emotions of title race says Arteta
-
Nepal temple celebrates return of stolen Buddha statue
-
US Fed official says rate hikes may be needed if inflation surges
-
Fixture pile-up no excuse for Man City in title race: Guardiola
-
Iran offers new proposal amid stalled US peace talks
-
Gulf countries' plans to bypass Hormuz still far off, experts warn
-
Luis Enrique says 'unique' PSG-Bayern first leg could have gone either way
-
Rebels take key military camp in Mali's north
-
Turkish police fire tear gas, arrest hundreds at Istanbul May Day rallies
-
Lufthansa apologises for lost Oscar after US airport security row
-
French hub monitors Hormuz tensions from afar
-
Flick happy Raphinha back for Barca with title in sight
-
UN troubled by rejected appeal of Cambodian opposition leader
-
Activists on Gaza aid flotilla detained by Israel disembark in Crete
-
Oil steady after wild swing, stocks diverge in thin trading
-
Lufthansa says searching for Oscar lost after US airport security row
-
Howe says Saudi backers are fully behind Newcastle
-
Chinese swimmer Sun Yang reports cyberbullying to police
-
Solomon Islands leader to face no-confidence vote after appeal court loss
-
Salah 'deserves big send-off', says Liverpool boss Slot
-
UK police charge man with stabbing attack on two Jewish Londoners
-
Solomon Islands leader loses court appeal, must face no confidence vote
-
Former world skating champion Uno joins pro eSports team
-
Japan baseball umpire hit by bat still unconscious two weeks on
-
Nakatani says won't be intimidated in sold-out Inoue title clash
-
T-Wolves eliminate Nuggets as Knicks demolish Hawks in NBA playoffs
-
Timberwolves eliminate Jokic's Nuggets from NBA playoffs
-
Arsenal seek to ramp up heat on Man City in title race
-
PSG closing in on another French title before Bayern second leg
-
Espanyol must stop rot against Real Madrid as Barca eye title
-
Leipzig can book return to Champions League as Bundesliga top-four rivals meet
-
Injuries add to Bath's challenge for Champions Cup semi in Bordeaux
-
Karius getting 'back to the top' with promotion-chasing Schalke
-
King Charles arrives in Bermuda after whirlwind US visit
-
Clashes erupt in Australian town over death of Indigenous girl
-
Iran war redraws sea routes with Africa as the pivot
-
India's cows offer biogas alternative to Mideast energy crunch
-
Afghans celebrate spring in bright red poppy fields
-
Finland's 'Flamethrower' and 4 other Eurovision favourites
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
J.Sauter--VB